September 29, 2026
Medtronic first said it would separate its Diabetes business in May 2025. That business became MiniMed Group, which listed on Nasdaq in March 2026. After the IPO, Medtronic still owned about 90% of the company.
The exchange offer launched on September 14 is meant to finish the job. Medtronic shareholders can swap their shares for MiniMed stock at a 7% discount, subject to an upper limit. The offer covers up to 225,361,295 MiniMed shares, or 80.1% of those outstanding. It is set to expire on October 9 unless extended. If the offer is oversubscribed, Medtronic plans to exchange its remaining stake as well. If it is not fully subscribed, Medtronic plans to dispose of the rest through a later spin-off, split-off, debt-for-equity exchange, or some combination of these.
CEO Geoff Martha described the rationale in two parts. Independence gives MiniMed its own focus and flexibility. It also lets Medtronic concentrate capital on its Cardiovascular, Neuroscience and Surgical portfolios.
In a message to MiniMed employees, the company said transition services remain in place while the separation completes. That detail matters for commercial hiring. Transition services agreements are temporary by design. A business that has relied on a parent's shared infrastructure eventually has to build its own. That means sales operations, contracting and pricing, commercial analytics, training and customer service, and a commercial leadership team that answers to its own board. The parent faces the reverse task. It redirects commercial investment toward the franchises it has chosen to prioritise.
Johnson & Johnson announced in October 2025 that it would separate its orthopaedics business. The standalone company would operate as DePuy Synthes, and J&J said it would be the largest orthopaedics-focused company in the world. The business generated about $9.2 billion in sales in fiscal 2024, and was widely reported at about $9.3 billion in 2025. J&J appointed Namal Nawana, the former CEO of Smith & Nephew, as Worldwide President to lead the business through the separation and beyond.
The structure is still undecided. On J&J's July earnings call, CFO Joseph Wolk said the company was still weighing all separation options and remained on track for a separation around mid-2027. In September, Bloomberg and the Wall Street Journal reported that J&J was in talks with Apollo over a transaction valuing DePuy Synthes at close to $20 billion. Both reports said a public spin-off was still possible, and neither company commented. No agreement had been announced as of this writing.
For commercial talent, the choice of path matters as much as the separation itself.
Either way, a prolonged period of uncertainty tends to make experienced orthopaedic reps, managers and commercial operations staff more open to conversations. Competitors know it.
Cooper's story is the most direct illustration of how portfolio questions become commercial hiring decisions.
On September 9, Cooper said it had completed the strategic review it began in December 2025. The board unanimously decided to keep CooperSurgical, saying the offers it received did not reflect the business's value. Cooper also raised its share repurchase authorisation from $2 billion to $3 billion. Among the operational changes that came out of the review, it said it was expanding CooperVision's global sales and marketing organisation.
On the earnings call, CEO Al White explained why:
Nine days later, Jana made public a letter to Cooper's board dated September 17. It said the company was suffering from "a crisis of its own creation." Jana asked the board to:
Jana is not the first activist here. MassDevice reports that Browning West wrote to Cooper's board last November, urging it to become a pure-play vision care company.
The result is a company recruiting into a significant US sales expansion while its leadership, structure and ownership are all being openly challenged. Candidates considering those roles will reasonably want to know how the plan holds up under whatever the board decides next.
The three stories differ in structure but point the same way. Portfolio decisions are now rewriting commercial organisations, not just balance sheets. Four shifts stand out.
Standalone-readiness roles. When a business leaves a larger parent, the functions it borrowed have to be rebuilt:
Companies that start hiring for these roles before transition services expire give themselves room to hire well rather than quickly.
Productivity over headcount. Under activist or private equity scrutiny, every commercial hire has to justify its return. Cooper frames its sales expansion as a return decision and pairs it with analytics tools. That is a sign of where the market is heading. Commercial analysts and sales operations leaders who can show territory-level return on investment are becoming as valuable as the reps themselves.
Leaders who have been through separations before. Standing up a commercial organisation, keeping top performers during uncertainty, and redesigning territories under new ownership are specific skills. J&J's choice of a former public-company CEO to lead DePuy Synthes through its separation shows how highly boards value that experience.
Harder questions from candidates. Strong commercial candidates now ask about ownership direction, transition timelines and whether comp plans will survive the next board decision. Hiring managers who can answer those questions clearly and early will have an advantage over those who can't.
For US MedTech hiring managers, the message is to plan commercial talent strategy alongside the deal, not after it closes. For commercial professionals, this reshuffle is creating real opportunity: new companies to build, new territories to open, and leadership roles that did not exist a year ago. 44 International works with MedTech commercial teams and candidates through exactly these transitions.
© All rights reserved